Insulin signaling and glucose transport in insulin resistant human skeletal muscle

[1]  S. Kane,et al.  AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain. , 2005, The Biochemical journal.

[2]  A. Aljada,et al.  Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  F. Liu,et al.  PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. , 2005, American journal of physiology. Endocrinology and metabolism.

[4]  T. Funahashi,et al.  Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy , 2005, Diabetologia.

[5]  S. Kane,et al.  Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. , 2005, Diabetes.

[6]  Xudong Huang,et al.  Differential Contribution of Insulin Receptor Substrates 1 Versus 2 to Insulin Signaling and Glucose Uptake in L6 Myotubes* , 2005, Journal of Biological Chemistry.

[7]  F. Lönnqvist,et al.  Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. , 2005, Diabetes.

[8]  Michael Stumvoll,et al.  Type 2 diabetes: principles of pathogenesis and therapy , 2005, The Lancet.

[9]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[10]  C. Homko,et al.  Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. , 2005, Diabetes.

[11]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[12]  T. McGraw,et al.  Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. , 2004, Molecular biology of the cell.

[13]  B. Hemmings,et al.  Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.

[14]  A. Schürmann,et al.  The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. , 2004, JPEN. Journal of parenteral and enteral nutrition.

[15]  G. Tsujimoto,et al.  Upregulation of the transcript level of GTPase activating protein KIAA0603 in T cells from patients with atopic dermatitis , 2004, FEBS letters.

[16]  J. Flier,et al.  Adipose Tissue as an Endocrine Organ , 2014 .

[17]  Ying Leng,et al.  Insulin Signaling Defects in Type 2 Diabetes , 2004, Reviews in Endocrine and Metabolic Disorders.

[18]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[19]  T. Sunderland,et al.  Regulation of the selenoprotein SelS by glucose deprivation and endoplasmic reticulum stress – SelS is a novel glucose‐regulated protein , 2004, FEBS letters.

[20]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[21]  G. Cartee,et al.  Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. , 2004, Diabetes.

[22]  Pgce CBiol Honorary Senior Fellow C Day PhD,et al.  Metformin: its botanical background , 2004 .

[23]  W. Piepersberg,et al.  Biotechnology and molecular biology of the α-glucosidase inhibitor acarbose , 2004, Applied Microbiology and Biotechnology.

[24]  M. Nauck,et al.  A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome , 2003, Acta Diabetologica.

[25]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[26]  M. Jensen,et al.  Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. , 2003, Diabetes care.

[27]  D. Wasserman,et al.  Regulation of hepatic and peripheral glucose disposal. , 2003, Best practice & research. Clinical endocrinology & metabolism.

[28]  M. Sajan,et al.  Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. , 2003, Diabetes.

[29]  R. Henry,et al.  Insulin-Stimulated Protein Kinase C λ/ζ Activity Is Reduced in Skeletal Muscle of Humans With Obesity and Type 2 Diabetes: Reversal With Weight Reduction , 2003 .

[30]  Y. Miyazaki,et al.  Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. , 2003, Diabetes.

[31]  S. Mudaliar,et al.  Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. , 2003, American journal of physiology. Endocrinology and metabolism.

[32]  J. Pankow,et al.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2003, Diabetes.

[33]  Y. Le Marchand-Brustel,et al.  Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. , 2003, Diabetes.

[34]  M. Mozzoli,et al.  Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. , 2003, Metabolism: clinical and experimental.

[35]  R. Guigó,et al.  Characterization of Mammalian Selenoproteomes , 2003, Science.

[36]  H. Koistinen,et al.  5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. , 2003, Diabetes.

[37]  John M Asara,et al.  Insulin-stimulated Phosphorylation of a Rab GTPase-activating Protein Regulates GLUT4 Translocation* , 2003, The Journal of Biological Chemistry.

[38]  G. Dohm,et al.  Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance. , 2003, Diabetes.

[39]  T. Sunderland,et al.  Elevation in Tanis expression alters glucose metabolism and insulin sensitivity in H4IIE cells. , 2003, Diabetes.

[40]  M. White,et al.  c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade* , 2003, The Journal of Biological Chemistry.

[41]  L. Niskanen,et al.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. , 2002, American journal of epidemiology.

[42]  D. Doddrell,et al.  Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. , 2002, Obesity research.

[43]  Robert L Hanson,et al.  Components of the "metabolic syndrome" and incidence of type 2 diabetes. , 2002, Diabetes.

[44]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[45]  J. Zierath,et al.  Gene expression of the p85α regulatory subunit of phosphatidylinositol 3-kinase in skeletal muscle from type 2 diabetic subjects , 2002, Pflügers Archiv.

[46]  Leslie Carter,et al.  Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. , 2002, Metabolism: clinical and experimental.

[47]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[48]  M. Febbraio,et al.  Muscle‐derived interleukin‐6: mechanisms for activation and possible biological roles , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  S. Kane,et al.  A Method to Identify Serine Kinase Substrates , 2002, The Journal of Biological Chemistry.

[50]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[51]  Vadim N. Gladyshev,et al.  How Selenium Has Altered Our Understanding of the Genetic Code , 2002, Molecular and Cellular Biology.

[52]  Ken Walder,et al.  Tanis: a link between type 2 diabetes and inflammation? , 2002, Diabetes.

[53]  Ansuman Bagchi,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Gene Expression Profile of Adipocyte Differentiation and Its Regulation by Peroxisome Proliferator-Activated , 2022 .

[54]  H. Klein,et al.  Insulin signalling in skeletal muscle of subjects with or without Type II-diabetes and first degree relatives of patients with the disease , 2002, Diabetologia.

[55]  H. Lodish,et al.  Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. , 2002, American journal of physiology. Endocrinology and metabolism.

[56]  P. Vollenweider,et al.  Insulin resistance, defective insulin receptor substrate 2-associated phosphatidylinositol-3' kinase activation, and impaired atypical protein kinase C (zeta/lambda) activation in myotubes from obese patients with impaired glucose tolerance. , 2002, Diabetes.

[57]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[58]  Vincent Lebon,et al.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.

[59]  L. Nolte,et al.  Glucose Transport in Skeletal Muscle , 2002 .

[60]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[61]  S. Mudaliar,et al.  Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. , 2002, Diabetes.

[62]  Lee-Ming Chuang,et al.  Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.

[63]  M. White,et al.  Phosphorylation of Ser307 in Insulin Receptor Substrate-1 Blocks Interactions with the Insulin Receptor and Inhibits Insulin Action* , 2002, The Journal of Biological Chemistry.

[64]  M. Matsuda,et al.  Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.

[65]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[66]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[67]  P. Raskin,et al.  A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. , 2001, Diabetes Care.

[68]  Y. Le Marchand-Brustel,et al.  The role of small G-proteins in the regulation of glucose transport (review). , 2001, Molecular membrane biology.

[69]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[70]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[71]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[72]  D. Cantrell.  Phosphoinositide 3-kinase signalling pathways. , 2001, Journal of cell science.

[73]  I. Sandoval,et al.  Moving the insulin-regulated glucose transporter GLUT4 into and out of storage. , 2001, Trends in cell biology.

[74]  M. D. Leibowitz,et al.  Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. , 2001, Molecular pharmacology.

[75]  T. Willson,et al.  Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues. , 2001, Endocrinology.

[76]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[77]  J. Krützfeldt,et al.  Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. , 2001, Biochemical and biophysical research communications.

[78]  Le Marchand-Brustel M. Cormont,.  The role of small G-proteins in the regulation of glucose transport , 2001 .

[79]  K. Petersen,et al.  Mechanism by which metformin reduces glucose production in type 2 diabetes. , 2000, Diabetes.

[80]  P. Wilson,et al.  Parental transmission of type 2 diabetes: the Framingham Offspring Study. , 2000, Diabetes.

[81]  A. Kessler,et al.  Rab11 is associated with GLUT4-containing vesicles and redistributes in response to insulin , 2000, Diabetologia.

[82]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[83]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[84]  K. Petersen,et al.  Mechanism of troglitazone action in type 2 diabetes. , 2000, Diabetes.

[85]  J. Rosenstock,et al.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.

[86]  J. Zierath,et al.  Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. , 2000, Diabetes.

[87]  J. Nolan,et al.  Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[88]  A. King.  A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. , 2000, Diabetes care.

[89]  X. Shen,et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.

[90]  Laville,et al.  Subcutaneous adipose tissue expression of tumour necrosis factor‐α is not associated with whole body insulin resistance in obese nondiabetic or in type‐2 diabetic subjects , 2000, European journal of clinical investigation.

[91]  P. Raskin,et al.  Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes , 2000, Diabetologia.

[92]  J. Zierath,et al.  Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. , 2000, Diabetes.

[93]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[94]  S. Mudaliar,et al.  Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. , 2000, Diabetes.

[95]  Y. Kido,et al.  Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. , 2000, The Journal of clinical investigation.

[96]  B. Wolffenbuttel,et al.  Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[97]  D. Alessi,et al.  Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.

[98]  T. Rönnemaa,et al.  Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes , 1999, Diabetologia.

[99]  R. Henry,et al.  Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. , 1999, The Journal of clinical investigation.

[100]  B. Kahn,et al.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. , 1999, The New England journal of medicine.

[101]  Z Trajanoski,et al.  Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. , 1999, The New England journal of medicine.

[102]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[103]  R. Anderson,et al.  Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study , 1999, Diabetes, obesity & metabolism.

[104]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[105]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[106]  Margaret S. Wu,et al.  Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action , 1998 .

[107]  T. Shimokawa,et al.  In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice. , 1998, Biochemical and biophysical research communications.

[108]  A. Newton,et al.  Regulation of protein kinase C ζ by PI 3-kinase and PDK-1 , 1998, Current Biology.

[109]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[110]  J. Zierath,et al.  Insulin-Stimulated Akt Kinase Activity Is Reduced in Skeletal Muscle From NIDDM Subjects , 1998, Diabetes.

[111]  S. Mudaliar,et al.  Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. , 1998, The Journal of clinical endocrinology and metabolism.

[112]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[113]  A. Baron,et al.  Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. , 1998, The Journal of clinical investigation.

[114]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[115]  A. Greenberg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Omental and Subcutaneous Adipose Tissues of Obese Subjects Release Interleukin-6: Depot Difference and Regulation by Glucocorticoid* , 1997 .

[116]  Y. Yazaki,et al.  Potential Role of Protein Kinase B in Insulin-induced Glucose Transport, Glycogen Synthesis, and Protein Synthesis* , 1998, The Journal of Biological Chemistry.

[117]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[118]  T. Buchanan,et al.  Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus , 1998, Annals of Internal Medicine.

[119]  J. Zierath,et al.  Improved Glucose Tolerance Restores Insulin-Stimulated Akt Kinase Activity and Glucose Transport in Skeletal Muscle From Diabetic Goto-Kakizaki Rats , 1997, Diabetes.

[120]  J. Pickup,et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.

[121]  R. Farese,et al.  Evidence for Involvement of Protein Kinase C (PKC)-ζ and Noninvolvement of Diacylglycerol-Sensitive PKCs in Insulin-Stimulated Glucose Transport in L6 Myotubes. , 1997, Endocrinology.

[122]  J. Zierath,et al.  Muscle-specific transgenic complementation of GLUT4-deficient mice. Effects on glucose but not lipid metabolism. , 1997, The Journal of clinical investigation.

[123]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[124]  J. Zierath,et al.  Insulin Receptor Substrate-1 Phosphorylation and Phosphatidylinositol 3-Kinase Activity in Skeletal Muscle From NIDDM Subjects After In Vivo Insulin Stimulation , 1997, Diabetes.

[125]  J. Zierath,et al.  High-Fat Feeding Impairs Insulin-Stimulated GLUT4 Recruitment via an Early Insulin-Signaling Defect , 1997, Diabetes.

[126]  M. Birnbaum,et al.  Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation* , 1996, The Journal of Biological Chemistry.

[127]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[128]  A. Klip,et al.  Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM , 1996, Diabetologia.

[129]  B. Portha,et al.  Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat. , 1996, The American journal of physiology.

[130]  K. Livak,et al.  Real time quantitative PCR. , 1996, Genome research.

[131]  B. Hemmings,et al.  Constitutive activation of protein kinase B and phosphorylation of p47 phox by a membrane-targeted phosphoinositide 3-kinase , 1996, Current Biology.

[132]  A. Klippel,et al.  Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways , 1996, Molecular and cellular biology.

[133]  Y. Le Marchand-Brustel,et al.  Diverse effects of Glut 4 ablation on glucose uptake and glycogen synthesis in red and white skeletal muscle. , 1996, The Journal of clinical investigation.

[134]  Simon C Watkins,et al.  The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. , 1996, The Journal of clinical investigation.

[135]  R. Burcelin,et al.  Enhanced Insulin Action Due to Targeted GLUT4 Overexpression Exclusively in Muscle , 1996, Diabetes.

[136]  M. Salminen,et al.  Improvement of Insulin Action in Diabetic Transgenic Mice Selectively Overexpressing GLUT4 in Skeletal Muscle , 1996, Diabetes.

[137]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[138]  H. Klein,et al.  Elevation of Serum Insulin Concentration During Euglycemic Hyperinsulinemic Clamp Studies Leads to Similar Activation of Insulin Receptor Kinase in Skeletal Muscle of Subjects With and Without NIDDM , 1995, Diabetes.

[139]  J. C. Aledo,et al.  Rab4, but not the transferrin receptor, is colocalized with GLUT4 in an insulin-sensitive intracellular compartment in rat skeletal muscle. , 1995, Biochemical and biophysical research communications.

[140]  A. Stenbit,et al.  Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4 , 1995, Nature.

[141]  R. Roth,et al.  Insulin stimulates the kinase activity of RAC‐PK, a pleckstrin homology domain containing ser/thr kinase. , 1995, The EMBO journal.

[142]  G. Bolstad,et al.  Muscle fibre type and dimension in genetically obese and lean Zucker rats. , 1995, Acta physiologica Scandinavica.

[143]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[144]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[145]  O. Pedersen,et al.  Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[147]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[148]  F. Giorgino,et al.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. , 1995, The Journal of clinical investigation.

[149]  M. Lane,et al.  High fat diet-induced hyperglycemia: prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[150]  J. Pessin,et al.  Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). , 1995, The Journal of clinical investigation.

[151]  J. Zierath,et al.  Development of decreased insulin-induced glucose transport in skeletal muscle of glucose-intolerant hybrids of diabetic GK rats. , 1995, Clinical science.

[152]  J. Pessin,et al.  Skeletal muscle glucose transport and metabolism are enhanced in transgenic mice overexpressing the Glut4 glucose transporter. , 1995, The Journal of biological chemistry.

[153]  Y. Ikeda,et al.  Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. , 1994, Clinical biochemistry.

[154]  C. González,et al.  Participation of Na+ channels in the response of carotid body chemoreceptor cells to hypoxia. , 1994, The American journal of physiology.

[155]  J. Zierath,et al.  Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM , 1994, Diabetologia.

[156]  C. Wilson,et al.  Insulin stimulation of glucose transport activity in rat skeletal muscle: increase in cell surface GLUT4 as assessed by photolabelling. , 1994, The Biochemical journal.

[157]  J. Zierath,et al.  Effects of glycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitro reversal of muscular insulin resistance , 1994, Diabetologia.

[158]  J. Olefsky,et al.  Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. , 1994, The Journal of clinical endocrinology and metabolism.

[159]  R. Bergman,et al.  Quantification of the Relationship Between Insulin Sensitivity and β-Cell Function in Human Subjects: Evidence for a Hyperbolic Function , 1993, Diabetes.

[160]  C. Kahn,et al.  Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. , 1993, The Journal of clinical investigation.

[161]  C. Kahn,et al.  Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. , 1993, The Journal of clinical investigation.

[162]  O. Pedersen,et al.  Glut 4 content in the plasma membrane of rat skeletal muscle: comparative studies of the subcellular fractionation method and the exofacial photolabelling technique using ATB‐BMPA , 1993, FEBS letters.

[163]  W. Soeller,et al.  Germline manipulation of glucose homeostasis via alteration of glucose transporter levels in skeletal muscle. , 1993, The Journal of biological chemistry.

[164]  M. Mueckler,et al.  Evidence from transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal muscle. , 1993, The Journal of biological chemistry.

[165]  E. Van Obberghen,et al.  Differential effects of okadaic acid on insulin-stimulated glucose and amino acid uptake and phosphatidylinositol 3-kinase activity. , 1993, The Journal of biological chemistry.

[166]  Dominique,et al.  Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice. , 1993, The Journal of clinical investigation.

[167]  D. Chisholm,et al.  The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. , 1993, The New England journal of medicine.

[168]  M J Saad,et al.  Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. , 1992, The Journal of clinical investigation.

[169]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[170]  H. Maegawa,et al.  Impaired Autophosphorylation of Insulin Receptors From Abdominal Skeletal Muscles in Nonobese Subjects With NIDDM , 1991, Diabetes.

[171]  D. Galuska,et al.  Decreased insulin-stimulated 3-0-methylglucose transport in in vitro incubated muscle strips from type II diabetic subjects. , 1991, Acta physiologica Scandinavica.

[172]  S. Corvera,et al.  Acute inhibition of insulin-stimulated glucose transport by the phosphatase inhibitor, okadaic acid. , 1991, The Journal of biological chemistry.

[173]  A. Klip,et al.  Stimulation of glucose transport in skeletal muscle by hypoxia. , 1991, Journal of applied physiology.

[174]  R. DeFronzo,et al.  Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. , 1991, The Journal of clinical investigation.

[175]  I. Simpson,et al.  Cell surface labeling of glucose transporter isoform GLUT4 by bis-mannose photolabel. Correlation with stimulation of glucose transport in rat adipose cells by insulin and phorbol ester. , 1990, The Journal of biological chemistry.

[176]  A. Vaag,et al.  Expression of insulin regulatable glucose transporters in skeletal muscle from Type 2 (non-insulin-dependent) diabetic patients , 1990, Diabetologia.

[177]  A. Klip,et al.  Exercise induces recruitment of the "insulin-responsive glucose transporter". Evidence for distinct intracellular insulin- and exercise-recruitable transporter pools in skeletal muscle. , 1990, The Journal of biological chemistry.

[178]  J. Flier,et al.  Evidence Against Altered Expression of GLUT1 or GLUT4 in Skeletal Muscle of Patients With Obesity or NIDDM , 1990, Diabetes.

[179]  E. Horton,et al.  Identification of an intracellular pool of glucose transporters from basal and insulin-stimulated rat skeletal muscle. , 1990, The Journal of biological chemistry.

[180]  L. Groop,et al.  Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. , 1989, The New England journal of medicine.

[181]  G I Bell,et al.  Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. , 1989, The Journal of biological chemistry.

[182]  M. Birnbaum.  Identification of a novel gene encoding an insulin-responsive glucose transporter protein , 1989, Cell.

[183]  H. Lodish,et al.  A glucose transport protein expressed predominately in insulin-responsive tissues. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[184]  D. James,et al.  Molecular cloning and characterization of an insulin-regulatable glucose transporter , 1989, Nature.

[185]  E. Horton,et al.  Acute exercise increases the number of plasma membrane glucose transporters in rat skeletal muscle , 1988, FEBS letters.

[186]  G. Dohm,et al.  An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. , 1988, The Journal of clinical investigation.

[187]  B. Hansen,et al.  Glucose-induced insulin resistance of skeletal-muscle glucose transport and uptake. , 1988, The Biochemical journal.

[188]  D. James,et al.  Insulin-regulatable tissues express a unique insulin-sensitive glucose transport protein , 1988, Nature.

[189]  G Sonnenberg,et al.  Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. , 1988, The Journal of clinical investigation.

[190]  P. Björntorp,et al.  Glucose uptake in human adipose tissue. , 1987, Metabolism: clinical and experimental.

[191]  A. Klip,et al.  Insulin‐induced translocation of glucose transporters in rat hindlimb muscles , 1987, FEBS letters.

[192]  H. Yki-Järvinen,et al.  Hyperglycemia Decreases Glucose Uptake in Type I Diabetes , 1987, Diabetes.

[193]  J. Henriksson,et al.  Reversibility of decreased insulin-stimulated glucose transport capacity in diabetic muscle with in vitro incubation. Insulin is not required. , 1987, The Journal of biological chemistry.

[194]  P. Arner,et al.  Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and Type 2 (non-insulin-dependent) diabetes mellitus , 1987, Diabetologia.

[195]  G. Dohm,et al.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. , 1987, The Journal of clinical investigation.

[196]  R. DeFronzo,et al.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.

[197]  E. Richter,et al.  Increased Muscle Glucose Uptake After Exercise: No Need for Insulin During Exercise , 1985, Diabetes.

[198]  H. Wallberg-henriksson,et al.  Activation of glucose transport in diabetic muscle: responses to contraction and insulin. , 1985, The American journal of physiology.

[199]  R. DeFronzo,et al.  Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. , 1985, The Journal of clinical investigation.

[200]  M. Trovati,et al.  Influence of Physical Training on Blood Glucose Control, Glucose Tolerance, Insulin Secretion, and Insulin Action in Non-insulin-dependent Diabetic Patients , 1984, Diabetes Care.

[201]  G. Dalsky,et al.  Glucose tolerance in young and older athletes and sedentary men. , 1984, Journal of applied physiology: respiratory, environmental and exercise physiology.

[202]  R. DeFronzo,et al.  The Effect of Insulin on the Disposal of Intravenous Glucose: Results from Indirect Calorimetry and Hepatic and Femoral Venous Catheterization , 1981, Diabetes.

[203]  R. Bergman,et al.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. , 1981, The Journal of clinical investigation.

[204]  B. Jeanrenaud,et al.  Potential mechanism of insulin action on glucose transport in the isolated rat diaphragm. Apparent translocation of intracellular transport units to the plasma membrane. , 1981, The Journal of biological chemistry.

[205]  J C Stanley,et al.  The glucose-fatty acid cycle. Relationship between glucose utilization in muscle, fatty acid oxidation in muscle and lipolysis in adipose tissue. , 1981, British journal of anaesthesia.

[206]  T. Kôno,et al.  Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[207]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[208]  K. Henriksson.  “Semi‐open” muscle biopsy technique A SIMPLE OUTPATIENT PROCEDURE , 1979, Acta neurologica Scandinavica.

[209]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[210]  G. Lienhard,et al.  Increased phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. , 2005, Diabetes.

[211]  D. Moller,et al.  Metabolic syndrome: a clinical and molecular perspective. , 2005, Annual review of medicine.

[212]  A. Aljada,et al.  Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.

[213]  L. J. Hardies,et al.  Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.

[214]  C. Östenson,et al.  Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat , 2004, Diabetologia.

[215]  R. Henry,et al.  Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. , 2003, Diabetes.

[216]  Joseph L Evans,et al.  Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? , 2003, Diabetes.

[217]  D. Gerhold,et al.  Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. , 2002, Endocrinology.

[218]  H. Lebovitz,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .

[219]  G. Striker.  Glucose toxicity. , 2001, Kidney international.

[220]  T. Willson,et al.  Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. , 2001, Endocrinology.

[221]  J. Berger,et al.  Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. , 1998, Endocrinology.

[222]  E. Van Obberghen,et al.  Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. , 1997, Endocrinology.

[223]  C. Wilson,et al.  Regulation of cell surface GLUT4 in skeletal muscle of transgenic mice. , 1997, The Biochemical journal.

[224]  R. Farese,et al.  Evidence for involvement of protein kinase C (PKC)-zeta and noninvolvement of diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes. , 1997, Endocrinology.

[225]  Y. Le Marchand-Brustel,et al.  Differential effects of insulin and exercise on Rab4 distribution in rat skeletal muscle. , 1996, Endocrinology.

[226]  E. Richter,et al.  Exercise-induced increase in glucose transport, GLUT-4, and VAMP-2 in plasma membrane from human muscle. , 1996, The American journal of physiology.

[227]  J. Zierath.  In vitro studies of human skeletal muscle: hormonal and metabolic regulation of glucose transport. , 1995, Acta physiologica Scandinavica. Supplementum.

[228]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[229]  G. Shulman,et al.  Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. , 1995, The Journal of clinical investigation.

[230]  B. Kahn,et al.  Suppression of GLUT4 expression in skeletal muscle of rats that are obese from high fat feeding but not from high carbohydrate feeding or genetic obesity. , 1993, Endocrinology.

[231]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[232]  H. Wallberg-henriksson,et al.  Glucose transport into skeletal muscle. Influence of contractile activity, insulin, catecholamines and diabetes mellitus. , 1987, Acta physiologica Scandinavica. Supplementum.

[233]  S. Cushman,et al.  Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. , 1980, The Journal of biological chemistry.